SCHEMBL29907468

SCHEMBL29907468

CC(C)(O)c1ccc(NC(=O)c2cccn(-c3ccc(F)c(F)c3OCC(F)(F)F)c2=O)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 6/20 0.72
MET P08581 5/20 0.41
AXL P30530 2/20 0.41
TYRO3 Q06418 1/20 0.41
MERTK Q12866 1/20 0.41
PPARG P37231 1/20 0.39
RAB9A P51151 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 3/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 2/20 0.37
TP53 P04637 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
RIPK3 Q9Y572 3/20 0.36
RIPK2 O43353 2/20 0.36
POLB P06746 1/20 0.36
RIPK1 Q13546 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29907521 0.85 UGCG (0.79) UGCGMETAXLTYRO3MERTK
SCHEMBL29907613 0.84 UGCG (0.83) UGCGMETAXLTYRO3MERTK
SCHEMBL29907592 0.84 UGCG (1.00) UGCGMETAXLTYRO3MERTK
SCHEMBL29907462 0.82 UGCG (0.83) UGCGMETAXLTYRO3MERTK
SCHEMBL29907581 0.81 UGCG (0.76) UGCGMETAXLTYRO3MERTK
SCHEMBL29907446 0.80 UGCG (0.71) UGCGMETAXLTYRO3MERTK
SCHEMBL24464290 0.78 UGCG (0.89) UGCGMETAXLTYRO3MERTK
SCHEMBL29907361 0.78 UGCG (0.89) UGCGMETAXLTYRO3MERTK
SCHEMBL29907598 0.78 UGCG (0.76) UGCGMETAXLTYRO3MERTK
SCHEMBL29907576 0.78 UGCG (0.72) UGCGMETAXLTYRO3MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289679-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289679-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC UGCG 10/4885MET 4830/4885AXL 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.